Biologically relevant 3D tumor arrays: Treatment response and the importance of stromal partners

Progress in Biomedical Optics and Imaging - Proceedings of SPIE

Volumn 7886, Issue , 2011, Pages

  Rizvi, Imran ^a   Celli, Jonathan P ^a   Xu, Feng ^b   Evans, Conor L ^a   Abu Yousif, Adnan O ^a   Muzikansky, Alona ^a   Elrington, Stefan A ^a   Pogue, Brian W ^c   Finkelstein, Dianne M ^a   Demirci, Utkan ^b   Hasan, Tayyaba ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DARTMOUTH COLLEGE   (United States)

Author keywords

3D tumor model; carboplatin; cell patterning; combination regimen; Heterocellular 3D tumor arrays; ovarian cancer; photodynamic therapy; stromal partners

Indexed keywords

CARBOPLATIN; CELL PATTERNING; COMBINATION REGIMEN; HETEROCELLULAR 3D TUMOR ARRAYS; OVARIAN CANCERS; STROMAL PARTNERS; TUMOR MODELS;

BATCH DATA PROCESSING; CELL CULTURE; DISEASES; ENDOTHELIAL CELLS; ENZYME INHIBITION; MONOLAYERS; PHOTODYNAMIC THERAPY; PLASMONS; TUMORS;

THREE DIMENSIONAL;

EID: 79954545145     PISSN: 16057422     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1117/12.875892     Document Type: Conference Paper

References (63)

1. J. Debnath, and J. S. Brugge, "Modelling glandular epithelial cancers in three-dimensional cultures," Nat Rev Cancer, 5(9), 675-88 (2005).
2. L. G. Griffith, and G. Naughton, "Tissue engineering - current challenges and expanding opportunities," Science, 295(5557), 1009-14 (2002).
3. L. G. Griffith, and M. A. Swartz, "Capturing complex 3D tissue physiology in vitro," Nat Rev Mol Cell Biol, 7(3), 211-24 (2006).
4. A. Rangarajan, and R. A. Weinberg, "Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice," Nat Rev Cancer, 3(12), 952-9 (2003).
5. T. Jacks, and R. A. Weinberg, "Taking the study of cancer cell survival to a new dimension," Cell, 111(7), 923-5 (2002).
6. W. Mueller-Klieser, "Three-dimensional cell cultures: from molecular mechanisms to clinical applications," Am J Physiol, 273(4 Pt 1), C1109-23 (1997).
7. P. M. Comoglio, and L. Trusolino, "Cancer: the matrix is now in control," Nat Med, 11(11), 1156-9 (2005).
8. D. Hanahan, and R. A. Weinberg, "The hallmarks of cancer," Cell, 100(1), 57-70 (2000).
9. D. Mahadevan, and D. D. Von Hoff, "Tumor-stroma interactions in pancreatic ductal adenocarcinoma," Mol Cancer Ther, 6(4), 1186-97 (2007).
10. C. Dennis, "Cancer: off by a whisker," Nature, 442(7104), 739-41 (2006).
11. N. A. Bhowmick, E. G. Neilson, and H. L. Moses, "Stromal fibroblasts in cancer initiation and progression," Nature, 432(7015), 332-7 (2004).
12. M. J. Bissell, V. M. Weaver, S. A. Lelievre et al., "Tissue structure, nuclear organization, and gene expression in normal and malignant breast," Cancer Res, 59(7 Suppl), 1757-1763s; discussion 1763s-1764s (1999).
13. J. Debnath, K. R. Mills, N. L. Collins et al., "The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini," Cell, 111(1), 29-40 (2002).
14. F. Gelain, D. Bottai, A. Vescovi et al., "Designer Self-Assembling Peptide Nanofiber Scaffolds for Adult Mouse Neural Stem Cell 3-Dimensional Cultures," PLoS ONE, e119(1), 1-11 (2006).
15. H. K. Kleinman, M. L. McGarvey, J. R. Hassell et al., "Basement membrane complexes with biological activity," Biochemistry, 25(2), 312-8 (1986).
16. D. C. Radisky, D. D. Levy, L. E. Littlepage et al., "Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability," Nature, 436(7047), 123-7 (2005).
17. K. S. Smalley, M. Lioni, and M. Herlyn, "Life isn't flat: taking cancer biology to the next dimension," In Vitro Cell Dev Biol Anim, 42(8-9), 242-7 (2006).
18. U. A. Stock, and J. P. Vacanti, "Tissue engineering: current state and prospects," Annu Rev Med, 52, 443-51 (2001).
19. B. Zavan, R. Cortivo, C. Tonello et al., "Gland cell cultures into 3D hyaluronan-based scaffolds," J Mater Sci Mater Med, 14(8), 727-9 (2003).
20. S. Zhang, T. C. Holmes, C. M. DiPersio et al., "Self-complementary oligopeptide matrices support mammalian cell attachment," Biomaterials, 16(18), 1385-93 (1995).
21. S. K. Muthuswamy, D. Li, S. Lelievre et al., "ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini," Nat Cell Biol, 3(9), 785-92 (2001).
22. T. Ohmori, J. L. Yang, J. O. Price et al., "Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy," Exp Cell Res, 245(2), 350-9 (1998).
23. O. J. Becher, and E. C. Holland, "Genetically engineered models have advantages over xenografts for preclinical studies," Cancer Res, 66(7), 3355-8, discussion 3358-9 (2006).
24. E. A. Sausville, and A. M. Burger, "Contributions of human tumor xenografts to anticancer drug development," Cancer Res, 66(7), 3351-4, discussion 3354 (2006).
25. J. A. DiMasi, and H. G. Grabowski, "Economics of new oncology drug development," J Clin Oncol, 25(2), 209-16 (2007).
26. FDA, [United States Food and Drug Administration].
27. N. E. Sharpless, "What Are the Best Preclinical Models for Cancer Drug Discovery?." 125.
28. J. B. Kim, "Three-dimensional tissue culture models in cancer biology," Semin Cancer Biol, 15(5), 365-77 (2005).
29. A. Rangarajan, S. J. Hong, A. Gifford et al., "Species- and cell type-specific requirements for cellular transformation," Cancer Cell, 6(2), 171-83 (2004).
30. J. P. Celli, B. Q. Spring, I. Rizvi et al., "Imaging and photodynamic therapy: mechanisms, monitoring, and optimization," Chem Rev, 110(5), 2795-838 (2010).
31. M. G. del Carmen, I. Rizvi, Y. Chang et al., "Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo," J Natl Cancer Inst, 97(20), 1516-24 (2005).
32. L. R. Duska, M. R. Hamblin, J. L. Miller et al., "Combination photoimmunotherapy and cisplatin: effects on human ovarian cancer ex vivo," J Natl Cancer Inst, 91(18), 1557-63 (1999).
33. T. Hasan, B. Ortel, N. Solban et al., [Photodynamic therapy of cancer] B.C. Decker, Inc., Hamilton, Ontario, 35a (2006).
34. K. Fujiwara, "Can carboplatin replace cisplatin for intraperitoneal use?," Int J Gynecol Cancer, 18 Suppl 1, 29-32 (2008).
35. U. Demirci, "Acoustic Picoliter Droplets for Emerging Applications in Semiconductor Industry and Biotechnology," Journal of Microelectromechanical Systems, 15(4), 957-966 (2006).
36. U. Demirci, and G. Montesano, "Cell encapsulating droplet vitrification," Lab Chip, 7(11), 1428-33 (2007).
37. S. Moon, S. K. Hasan, Y. S. Song et al., "Layer by layer three-dimensional tissue epitaxy by cell-laden hydrogel droplets," Tissue Eng Part C Methods, 16(1), 157-66 (2010).
38. F. Xu, J. Celli, I. Rizvi et al., "A three-dimensional in vitro ovarian cancer coculture model using a high-throughput cell patterning platform," Biotechnol J, 6(2), 204-12 (2011).
39. F. Xu, S. Moon, A. E. Emre et al., "A droplet based building block approach for bladder smooth muscle cell (SMC) proliferation," Biofabrication, doi:10.1088/1758-5082/2/1/014105 (2010).
40. J. P. Celli, I. Rizvi, C. L. Evans et al., "Quantitative imaging reveals heterogeneous growth dynamics and treatment-dependent residual tumor distributions in a three-dimensional ovarian cancer model," Journal of Biomedical Optics, 15(5), 051603-10 (2010).
41. I. Rizvi, J. P. Celli, C. L. Evans et al., "Synergistic Enhancement of Carboplatin Efficacy with Photodynamic Therapy in a Three-dimensional Model for Micrometastatic Ovarian Cancer," Cancer Research, 70(22), 9319-28 (2010).
42. O. W. Petersen, L. Ronnov-Jessen, A. R. Howlett et al., "Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells," Proc Natl Acad Sci U S A, 89(19), 9064-8 (1992).
43. G. Y. Lee, P. A. Kenny, E. H. Lee et al., "Three-dimensional culture models of normal and malignant breast epithelial cells," Nat Methods, 4(4), 359-65 (2007).
44. J. Debnath, S. K. Muthuswamy, and J. S. Brugge, "Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures," Methods, 30(3), 256-68 (2003).
45. J. P. Celli, I. Rizvi, C. L. Evans et al., "3D ovarian cancer models: imaging and therapeutic combinations," Proc. SPIE, 7551, (2010).
46. Y. S. Song, D. Adler, F. Xu et al., "Vitrification and levitation of a liquid droplet on liquid nitrogen," Proc Natl Acad Sci U S A, 107(10), 4596-600 (2010).
47. J. Celli, I. Rizvi, A. Blanden et al., "Biologically-relevant 3D tumor arrays: Imaging-based methods for quantification of reproducible growth and analysis of treatment response," Proc SPIE, 7886-7, (2011).
48. J. Celli, I. Rizvi, A. Blanden et al., "Imaging Enabled Platforms for Development of Therapeutics," Proc SPIE, 7910-1, (2011).
49. K. L. Molpus, M. R. Hamblin, I. Rizvi et al., "Intraperitoneal Photoimmunotherapy of Ovarian Carcinoma Xenografts in Nude Mice Using Charged Photoimmunoconjugates," Gynecol Oncol, 76(30), 397-404 (2000).
50. K. L. Molpus, D. Kato, M. R. Hamblin et al., "Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model," Cancer Res, 56(5), 1075-82 (1996).
51. K. L. Molpus, D. Koelliker, L. Atkins et al., "Characterization of a xenograft model of human ovarian carcinoma which produces intraperitoneal carcinomatosis and metastases in mice," Int J Cancer, 68(5), 588-95 (1996).
52. M. Markman, "Pharmaceutical management of ovarian cancer : current status," Drugs, 68(6), 771-89 (2008).
53. M. Markman, "Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin," Ther Clin Risk Manag, 5(1), 161-8 (2009).
54. L. R. Duska, M. R. Hamblin, J. L. Miller et al., "Photoimmunotherapy in combination with cisplatin for the treatment of advanced ovarian cancer," J.Natl.Cancer Inst., submitted, (1998).
55. C. Menon, S. N. Kutney, S. C. Lehr et al., "Vascularity and uptake of photosensitizer in small human tumor nodules: implications for intraperitoneal photodynamic therapy," Clin Cancer Res, 7(12), 3904-11 (2001).
56. H. A. Kenny, S. Kaur, L. M. Coussens et al., "The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin," J Clin Invest, 118(4), 1367-79 (2008).
57. H. A. Kenny, T. Krausz, S. D. Yamada et al., "Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum," Int J Cancer, 121(7), 1463-72 (2007).
58. K. M. Burleson, M. P. Boente, S. E. Pambuccian et al., "Disaggregation and invasion of ovarian carcinoma ascites spheroids," J Transl Med, 4, 6 (2006).
59. K. M. Burleson, R. C. Casey, K. M. Skubitz et al., "Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers," Gynecol Oncol, 93(1), 170-81 (2004).
60. K. M. Burleson, L. K. Hansen, and A. P. Skubitz, "Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers," Clin Exp Metastasis, 21(8), 685-97 (2004).
61. N. Ahmed, E. W. Thompson, and M. A. Quinn, "Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm," J Cell Physiol, 213(3), 581-8 (2007).
62. R. Kalluri, and M. Zeisberg, "Fibroblasts in cancer," Nat Rev Cancer, 6(5), 392-401 (2006).
63. U. Demirci, and G. Montesano, "Single cell epitaxy by acoustic picolitre droplets," Lab Chip, 7(9), 1139-45 (2007).